IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients

IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum‐based chemotherapy as first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC). Key eligibility criteria for the phase 3, open‐label, IMpower132 study included age ≥18 y, histologically or cytologica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Sci
Asıl Yazarlar: Nishio, Makoto, Saito, Haruhiro, Goto, Koichi, Watanabe, Satoshi, Sueoka‐Aragane, Naoko, Okuma, Yusuke, Kasahara, Kazuo, Chikamori, Kenichi, Nakagawa, Yuki, Kawakami, Tomohisa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2021
Konular:
ORIGINAL ARTICLES
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8019191/
https://ncbi.nlm.nih.gov/pubmed/33462883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14817
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller